COMMENTARY



Open Access

Assessing and presenting summaries of evidence in Cochrane Reviews

Miranda W Langendam^{1*}, Elie A Akl², Philipp Dahm^{3,4}, Paul Glasziou⁵, Gordon Guyatt⁶ and Holger J Schünemann⁶

Abstract

Cochrane Reviews are intended to help providers, practitioners and patients make informed decisions about health care. The goal of the Cochrane Applicability and Recommendation Methods Group (ARMG) is to develop approaches, strategies and guidance that facilitate the uptake of information from Cochrane Reviews and their use by a wide audience with specific focus on developers of recommendations and on healthcare decision makers. This paper is part of a series highlighting developments in systematic review methodology in the 20 years since the establishment of The Cochrane Collaboration, and its aim is to present current work and highlight future developments in assessing and presenting summaries of evidence, with special focus on Summary of Findings (SoF) tables and Plain Language Summaries.

A SoF table provides a concise and transparent summary of the key findings of a review in a tabular format. Several studies have shown that SoF tables improve accessibility and understanding of Cochrane Reviews.

The ARMG and GRADE Working Group are working on further development of the SoF tables, for example by evaluating the degree of acceptable flexibility beyond standard presentation of SoF tables, developing SoF tables for diagnostic test accuracy reviews and interactive SoF tables (iSoF).

The plain language summary (PLS) is the other main building block for dissemination of review results to end-users. The PLS aims to summarize the results of a review in such a way that health care consumers can readily

understand them. Current efforts include the development of a standardized language to describe statistical results, based on effect size and quality of supporting evidence.

Producing high quality PLS and SoF tables and making them compatible and linked would make it easier to produce dissemination products targeting different audiences (for example, providers, health policy makers, guideline developers).

Current issues of debate include optimal presentation formats of SoF tables, the training required to produce SoF tables, and the extent to which the authors of Cochrane Reviews should provide explicit guidance to target audiences of patients, clinicians and policy-makers.

Background

Cochrane Reviews are intended to help providers, practitioners and patients make informed decisions about health care. After collecting, appraising and analyzing the evidence, assessment and presentation of summaries of the evidence support the process of going from evidence to recommendations. The Applicability and Recommendation Methods Group (ARMG) has been largely responsible for developing the methodology for this part of Cochrane Reviews, which deal with interpretation of

* Correspondence: m.w.langendam@amc.uva.nl

¹The Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

the results of the reviews and facilitating the uptake of the information they contain. In this paper we will present the different summary presentations, and discuss their rationale, current format, added value and future development. We will focus on Summary of Findings (SoF) tables and plain language summaries (PLS) as they are the main building blocks for dissemination of review results to end-users. We start by outlining the work of the ARMG and the link with GRADE Working Group.

The applicability and recommendation methods group *History*

Following an exploratory meeting in 1995 at the Cochrane Colloquium in Oslo, the ARMG was established



© 2013 Langendam et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full list of author information is available at the end of the article

to look at the applicability of review results to different groups of patients and how to best present the results of Cochrane Reviews so that they would be readily understood and widely used. Key issues included considerations on how to best present a summary of the magnitude of effect for beneficial and harmful effects, transparently identifying predictable causes of heterogeneity in the absolute effects, the influence of individual risk or severity of illness on net effect, and patient's values and circumstances [1].

The new group, convened by Paul Glasziou and Gordon Guyatt, initially focused on the review and development of methods for addressing these issues, partly supported by a review of past work commissioned by the Australian National Health and Medical Research Council [2]. The group had some input to a section of the Cochrane Handbook, and developed a five-step process that began with a summary of the main benefits and harms.

As The Cochrane Library became more complete and mature, the issues of applicability and recommendations became more important to users of reviews. At the same time, the awareness arose that users need optimal succinct structured and reasonably uniform summaries to understand the key findings of the often comprehensive Cochrane Reviews and to facilitate judgments on applicability. Therefore, in 2004, at the Cochrane Colloquium in Ottawa, Paul Glasziou and Andy Oxman led empirical work at an ARMG workshop exploring contents of a SoF table which would summarize the main beneficial and harmful effects in a tabular format. This idea and a draft SoF table was warmly received.

Encouraged by the work of the ARMG while at the Ottawa workshop, and after being offered co-leadership of the group, Holger Schünemann replaced Paul Glasziou as co-convenor of the ARMG. As there was much overlap among the work of the GRADE working group, more intense work on common aims resulted. For example, Holger Schünemann and Andy Oxman had led the GRADE Working Group in producing the GRADE profiler software (GRADEpro) to produce the SoF tables and integrate with RevMan. Through work under the umbrella of the ARMG and the GRADE working group, the SoF table has been further developed. Since then, there has been a slow but steady uptake of the SoF tables, which have improved the usability of reviews, and implemented a substantial part of the original agenda of the ARMG.

Current aim

In 2013, the mission of the ARMG was refined, becoming "to develop approaches, strategies, and guidance that support the dissemination of Cochrane Reviews and their use by a wide range of audience with specific focus on developers of recommendations (including guidance, guidelines, policies) and on healthcare decision makers (e.g. clinicians, policy makers)".

Specifically, the ARMG provides guidance to optimize the usefulness of Cochrane Reviews by articulating reasons for grading the quality of the evidence and factors to consider when moving from evidence to recommendations. The group also provides detailed guidance to authors of Cochrane Reviews on how to apply the factors, and to users of Cochrane Reviews on how to interpret the judgments made by review authors. This includes guidance on providing the systematic review audience with the information necessary to make judgments about applicability and on making direct statements about applicability. For example, the Cochrane Handbook for Systematic Reviews of Interventions explains what the review author can do to help the user to apply the study findings to the population at large or a specific person: "Cochrane review authors must be extremely clear on the population, intervention, and outcomes that they are intending to address. A crucial step is the specification of all patient-important outcomes relevant to the intervention strategies under comparison" [3].

The ARMG also takes responsibility for training the editorial teams of Cochrane Review Groups and review authors to enable the development of SoF tables. Members of the ARMG conduct research on the applicability and the presentation of evidence. In addition, the group disseminates relevant research conducted by its members and other investigators.

Membership, scope of work and objectives of the ARMG overlap with those of the GRADE Working Group (in fact, at the Melbourne Colloquium in 2005, the GRADE Working Group considered whether or not they should merge with the ARMG and operate under the Cochrane umbrella only). The GRADE Working Group began in the year 2000 as an informal collaboration of people with an interest in addressing the shortcomings of grading systems in health care. The working group has developed a common, sensible and transparent approach to grading quality of evidence and strength of recommendations and is working to improve this approach. Many international organizations have provided input into the development of the approach and have started using it (www.gradeworkinggroup.org). Through numerous workshops and training events the GRADE working group has both disseminated the SoF tables and enhanced the profile of the ARMG.

Summary presentation of evidence in Cochrane Reviews

The Cochrane Collaboration launched several initiatives in recent years to develop and evaluate summaries of Cochrane Reviews for different target groups [4]. The SoF table was developed mainly for health professionals [4,5], while different formats of the PLS have been developed mainly for consumers [6,7].

There has been a realization over the last few years that health professionals may not be at much more ease than consumers in understanding and interpreting statistical information, even when presented in a SoF table. At the same time, some consumers might be interested in more detailed information than that presented in a PLS.

Summary of findings tables

SoF tables are becoming an integral part of Cochrane Reviews by providing a concise and transparent summary of the key findings of a review. At present, SoF tables are more frequently used in Cochrane Reviews than in other systematic reviews and studies have demonstrated that they improve the accessibility and understanding of Cochrane Reviews [4,5]. However, they have been featured in prominent journals, such as *The New England Journal of Medicine* [8].

SoF tables aim to provide a succinct, easily interpretable presentation of the evidence for healthcare providers to make well-informed decisions [9,10]. Critical elements include the confidence in the effect estimates (quality of evidence) and magnitude of effects. The system of assessing the quality of the evidence was developed by the GRADE Working Group [11] and adopted by the Cochrane Collaboration.

Format

The current format of the SoF table is the product of several initiatives of the ARMG and the GRADE Working Group to develop and evaluate summaries of Cochrane Reviews for different target groups [12]. Examples of the current format of a SoF table are presented in Figure 1. The types of information that could be included in a SoF table are as follows:

- 1) A list of all important outcomes; both desirable and undesirable.
- 2) A measure of the typical burden of these outcomes (for example, control group risk, estimated risk).
- A measure of the risk in the intervention group, (or alternatively, or in addition, a measure of the difference between the risks with and without the intervention).
- 4) The relative magnitude of effect.
- 5) The numbers of participants and studies addressing these outcomes.
- 6) A rating of the overall confidence in effect estimates for each outcome (which may vary by outcome).
- 7) And possibly, a comments section that provides clarification and/or additional information.

Supported by the Cochrane Methods Innovation Fund (MIF), the groups are currently working on alternative formats for the SoF tables.

The SoF table differs from GRADE evidence profiles (EP) in the presentation of the quality assessment of each factor that determines the quality of evidence for each outcome (for example, the reason for downgrading due to study limitations). In GRADE EP this is presented in detail, while in the SoF table the quality of the evidence assessment is only provided in key information needed for decision-making. They represent a compromise between simplicity (to make information as easily understandable to a wide audience) and completeness (to make the information and the underlying judgments as transparent as possible, but avoiding unnecessary detail).

Outcomes

SoF tables present the outcomes that have been judged to be critical for decision-making. Each of these outcomes should be patient-important rather than a surrogate outcome and their number should be limited to seven, a result of the work done at the workshop at the Cochrane Colloquium in Ottawa in 2004. The choice of seven outcomes, however, is also based on work in the field of psychology, indicating that humans find it difficult differentiating beyond seven factors, and serves the purpose of keeping the presented information manageable [12]. This requires authors of Cochrane Reviews to prioritize outcomes based on their perceived importance (ideally, at a very early stage of the work on their review) as well as potentially aggregating related, yet different, outcomes of approximately equal importance in one outcome measure (for example, combined outcome of gastrointestinal side-effects for patient risk for experiencing either vomiting and/or diarrhea).

Although the SoF table should focus on the patientimportant outcomes, there are situations in which there may not be direct evidence for these outcomes. In that case, reviewers should present their inferences regarding treatment effect from the surrogate outcomes measure; and this should be clearly labeled. The authors would do this by using the best estimate of the baseline risk for the patient-important outcome (see below) and then applying the relative effect from the surrogate outcome.

Another special situation may arise when the quality of evidence is low or very low for the relevant, patientimportant outcome and a related, indirect outcome measure exists that is (rightly or wrongly) perceived to be highly relevant by the clinical community. In such situations, indirect evidence may be presented, but authors should be explicit about its role as a surrogate measure.

In general, SoF tables should present the highest quality of evidence available for a given outcome. When the

g956 CI) Corresponding (90% CI) effect (90% CI) participants (studies) of the evidence (GRADE) symptomatic leve vinin htrombosis (DVT) See comment (studies) See comment (studies) Not estimable (9 studies) See comment (studies) See comment (studies) Symptomatic leve vinin htrombosis (DVT) Low risk population 2 (0 to 3) Not estimable (studies) See comment (studies) See comment (studies) Not estimable (studies) Symptomatic leve vinin htrombosis 13 per 1000 (studies) RR 0.45 (2 to 15) 1804 (studies) ++++ Moderate ³ Superficial win normal costs (studies) 13 per 1000 (studies) RR 0.45 (studies) 1804 (studies) +++O Moderate ³ Superficial win normal costs (studies) 13 per 1000 (studies) RR 0.45 (studies) 1804 (studies) +++O Moderate ³ Superficial win (n, no costem, (studies, 1) 13 per 1000 (studies) KR 0.45 (studies) 1804 (studies) +++O Moderate ³ Full The mean (Sti S) 6 to S Not estimable (studies) See comment (studies, 1) Not estimable (studies, 1) See comment (studies, 2) Not estimable (studies, 2) Full See comment (studies, 1) Not estimable (studies) See comment (studies, 2) Not estimable (studies, 2)	Summary of findin	gs:					
Bettings: International air travel Intervention: Compression stockings ¹ Domarises: Without stockings Datamase: Without stockings Datamase: Without stockings Without with stockings Symptomatic Symptomatic Symptomatic Best comment: See comment: <	Compression stor	kings comp	ared with no co	ompression s	tockings for	people takir	ng long flights
Intervention: Compression stockings ¹ Comparison: Without stockings Valuations Without stockings Valuations Without stockings Valuations Comparison: Without stockings Valuations Without stockings Valuations Without stockings Valuations See comment () periodicities () periodi	Patients or popula	ation: Anyone	e taking a long fli	ight (lasting mo	ore than 6 hou	urs)	
Comparison: Without stockings	Settings: Internation	onal air travel					
Dubbances Illustrative comparative risks (20% C) Variability effect max section Variability of the students Commonts of the evaluation Commonts of the section Symptomatic teep vanin herebusis See comment See comment (10 0 3) Not estimative (20 0 4 10 2.2) See comment 0 participants developed symptomatics See comment 0 participants developed symptomatics Symptomatics See comment (10 0 3) RR 0.10 2637 +++++ High risk population ² RR 0.10 2637 +++++ High risk population ² (0 0 4 10 - 20) (9 studies) ++++O Mithout (10 0 0) (10 - 6) (0 + 10 - 20) (9 studies) ++++O Moderata ³	Intervention: Com	pression stoc	kings ¹				
 	Comparison: With	out stockings					
Assund risk Consequencing risk Gift Cl (gift Cl) (studen) Consequence (GRADE) Symptomalics See comment See comment Not estimate 2221 See comment 0 participants developed symptomalics Symptom-less Cov risk population 2 RR 0.10 2537 +++++ High risk population 2 RR 0.10 2537 +++++ High risk population 2 RR 0.10 (9 studes) ++++O Superficial with thrombosis 13 per 1000 (10 to 3) (10 to 3) (0.4 to 0.26) (9 studes) Additional difference (10 to 3) Superficial with thrombosis 13 per 1000 (2 to 15) (0.18 to 1.13) (9 studes) Moderate ³ Defensa The main thrombosis 13 per 1000 (2 to 15) (0.18 to 1.13) (9 studes) everage Valideria The main thrombosis 13 per 1000 (10 to 3) (10 to 3) (10 to 3) Valideria (2 to 15) (0.18 to 1.13) (9 studes) everage (10 to 3) Valideria See comment See comment Not estimate	Outcomes		mparative risks*				Comments
Sauded tax Case Comment See comment			Corresponding				
Without With slockings See comment is see comment. See comment is see comment. Not estimable 2821 See comment 0 participants developed studies. Symptom-less Low risk population 2 RR 0.10 2837 +++++ Bige reliable (0 to 3) (0 to 0.26) (9 studies) High High risk population 2 RR 0.40 (0 to 0.26) (9 studies) High Superficial win 13 per 1000 6 per 1000 (1 to 6) (1 to 6) (1 to 6) Superficial win 13 per 1000 6 per 1000 (1 to 6) (1 to 6) Moderate ³ Ordering core goods as core order goods goods as core orderas core order goods goods as core order goods goods as		Assumed risk		(95% CI)	(01000)		
Symptomatic kep vin hrombosis See comment See comment Not estimable 221 (9 studies) See comment (0 participants developed symptomatic DVT in these studies. in per 1000 (0 1 is 0) High risk population ² 30 per 1000 (1 to 8) High risk population ² 30 per 1000 (1 to 8) RR 0.10 30 per 1000 (1 to 8) RP 0.10 (1 to 8) RP 0.00 (1 to 8) (2 to 15) (1 to 8) RP 0.45 1804 +++O Moderate ³			With stockings			(GRADE)	
step vein trombosis Low risk population ? RR 0.10 2637 +++++ teep vein trombosis 10 per 1000 1 per 1000 (0 to 3) (0 to 3) High risk population ? 30 per 1000 3 per 1000 (0 to 3) High risk population ? 30 per 1000 3 per 1000 (1 to 5) Superficial vain 13 per 1000 6 per 1000 (1 to 5) (1 to 5) (1 to 5) (1 to 5) (1 to 5) Superficial vains 13 per 1000 6 per 1000 (1 to 5) (2 to 15) (1 to 6) RR 6.45 1804 ++++O Moderate 30 per 1000 3 per 1000 (1 to 5) (1 to 5) (2 to 15) (1 to 6) RR 6.45 1804 +++O Moderate 4++O Moderate 4++O (2 to 15) (1 to 8) Low ⁴ ++OO (9 studies) See comment () participants developed palmonary embolus in these studies. formal array arrays Not estimable 2821 See comment () participants developed veigen arrays See comment () participants developed studies) studies <t< td=""><td>Symptomatic</td><td></td><td>See commont</td><td>Not estimable</td><td>2821</td><td>See common</td><td>t 0 narticinants developed</td></t<>	Symptomatic		See commont	Not estimable	2821	See common	t 0 narticinants developed
Internet Signal Low risk population 2 RR 0.10 203 + ++++ Symptom-less 10 per 1000 10 per 1000 (0 to 0.26) (9 studies) High High risk population 2 00 or 3 per 1000 (0 to 0.26) (9 studies) High Superficial vein 13 per 1000 6 per 1000 (0 to 0.26) (9 studies) High Superficial vein 13 per 1000 6 per 1000 (0 to 0.26) (9 studies) Moderata ³ Determa The mean The mean 1246 +++OO Moderata ³ Determa from access or in ranged across the intervention ranged across the intervention across or in ranged across the intervention across or from acreage (6 studies) Low ⁴ Pulmonary embolus See comment Not estimable 2821 See comment 0 participants developed pulmorary embolus in these studies. ⁵ Pulmonary embolus See comment Not estimable 2821 See comment Te identiality of the stockey or you with no complaints or you you with no complaints or you you with the relative effects See comment 1 Not estimable 2821 See comment Te identiality of the stockey or you with the relative effect of the intervertion (and is stops: C1). C1: Confidence interval; in the states included in thereive were below-knee compression stocking	deep vein	See comment	See comment	NULESUINADIE		See commen	symptomatic DVT in these
Peep vain prombosis I 0 per 1000 (0 to 3) 1 0 per 1000 (0 to 3) 0.04 to 0.26) (9 studies) High high prombosis Big per 1000 30 per 1000 10 to 8) 30 per 1000 (2 to 15) 0 per 1000 (2 to 15) RR 0.45 (0.18 to 1.13) 1804 (6 studies) +++O Moderata ³ Dedema nessued on a cacle operating values of 0, no edema 0, maximum The mean registed across the intervention from average of 0, no edema score from 0, no edema score from 1182 See comment 1182 See comment 0, per 10 per							studies.
Intrombosis In per local in per local in per local in the order and one of the order and one order and one order and one order order and one order and one order and order	• •						
High risk population 2 30 per 1000 3 per 1000 (1 to 6) Buperficial viein 13 per 1000 6 per 1000 (0.16 to 1.13) (8 studies) Moderata ³ (0.16 to 1.13) (0.16 to 1.13) (8 studies) Moderata ³ Dedema The mean The mean (1.6 to 1.13) (6 studies) Low ⁴ Oct-flight values measured or a scale (0, maximum 6 to 2, -4.5) (6 studies) Low ⁴ Control Pullinonary embolus See comment See comment Not estimable 2821 See comment To participants developed pulmonary embolus See comment Not estimable 2821 See comment To participants developed pulmonary embolus See comment Not estimable 2821 See comment To participants developed pulmonary embolus See comment Not estimable 1182 See comment To participants developed pulmonary embolus See comment Not estimable 1182 See comment To participants developed pulmonary embolus See comment Not estimable 1182 See comment To participants developed pulmonary embolus See comment Not estimable (4 studies) studies. Studies Studies Studies Studies Studies Studies St	thrombosis	10 per 1000		(0.04 to 0.26)	(9 studies)	High	
30 per 1000 3 per 1000 (1 to 8) Superficial vein intrombosis 13 per 1000 6 per 1000 (2 to 15) (0, 18 to 1.13) (8 studies) Dedema opdema score Inte mean of the mean of opdema score (6 studies) Moderata ³ Dedema opdema score arranged across the intervention of scale (6 studies) Low ⁴ 0, maximum edema. 6 to 9. 4.7 lower (95% Cl - 4.9 to - 4.5). Low ⁴ Pulmonary embolus See comment See comment Not estimable 2821 See comment 0 participants developed gumonary embolus in these studies. Pulmonary embolus See comment See comment Not estimable 2821 See comment 0 participants dei in these studies. Adverse effects See comment Not estimable 1182 See comment The tolerability of the stocking is no power of the intervention group and the relative effect of the intervention (and its 95% Cl). Confidence interval; is based on the sasued risk is provided in footnotes. The corresponding risk (and its 95% Cl). Confidence interval; RR: Risk ratio GRADE: Working Stroug grades of evidence (see explanations) 1 At the tookser prior to traits mound be neared in carrier of the and intervertion (and its 95% Cl). Confidence interval; is the stocking ato con the hoase prior to traits in compression							
uperficial vein hrombosis 13 per 1000 6 per 1000 (1 to 8) uperficial vein hrombosis 13 per 1000 6 per 1000 (2 to 15) (0.18 to 1.13) (8 studies) Deterna The mean ordema score on output groups was on average The mean ordema score (16 studies) The mean proget across the intervention groups was on average 1246 +++O Moderate ³ On maintum edema. The mean ordema score (16 studies) The mean (16 studies) 1246 +++O Low ⁴ Pullmonary embolus See comment Not estimable (9 studies) See comment 0 participants developed pulmonary embolus in these studies. ⁵ Pullmonary embolus See comment Not estimable (9 studies) See comment 0 participants developed pulmonary embolus in these studies. ⁵ Veith See comment Not estimable (9 studies) See comment 0 participants developed pulmonary embolus in these studies. ⁶ The basis for the assumed risk is provided in footnotes. The basis for the assumed risk is provided in footnotes. C: Confidence interval; R: Risk ratio GRADE: GRADE: GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 triatis included in the review were below-knee compression stockings. In four triatis the compression stockings. In four this the rower of the triats. The average of avidence interval; R: Risk ratio GRADE: GRADE: Working Group grades of vidence (see explanatio							
Superficial vein thrombosis 13 per 1000 6 per 1000 (2 to 15) RR 0.45 1804 +++O Moderate ³ The mean orderma score ranged across the intervention (0, macmum edems. The mean orderma score ranged across the intervention groups was on average 1246 +++O 0, macmum edems. The mean orderma score from The mean orderma score ranged across from 1246 ++OO 0, macmum edems. 6 to 9. 4.7 lower (6 studies) Low ⁴ 2ulmonary embolus See comment Not estimable 2821 See comment 0 participants developed pulmonary embolus in these studies. Paint See comment Not estimable 2821 See comment 0 participants developed pulmonary embolus in these studies. Paint See comment Not estimable 2821 See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the samed risk in the intervention group and the relative effect of the intervention (and its 95% coll. C1: Confidence interval; RX: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 traits included in thits reviewe were below-knee compression stockings. ac		30 per 1000					
hrombosis (2 to 15) (2 to 15) (2 to 15) (2 to 15) Moderate ³ Deferma The mean <	Cuparfield	12 nos 1000		DD 0.45	1904	-	
Determal rose-flight values nessured or a scale normal group across the intervention control group across the intervention option group across the intervention option group across the intervention on thom average 6 to 9. 1246 ++OO Unamonum 0, maximum edema. 10, maximum 6 to 9. 4,7 lower (95% CI -4.9 to -4.5). Low ⁴ Pullmonary embolus bee comment See comment Not estimable 2821 See comment 0 participants developed pulmonary embolus in these studies. Death See comment Not estimable 2821 See comment 0 participants developed gl studies) Adverse effects See comment Not estimable 2821 See comment to technologies as developed gl studies) The basis for the assumed risk is provided in footnotes. Not estimable 1182 See comment the tolerability of the studies. CI: confidence interval; RR: Risk ratio GRADE: GRADE: Working Group grades of evidence (see explanations) In the stockings in the first included in this review were below-knee compression stockings. In four trials the compression stockings should be flited pression stocking as house to be alway being across of the dista could be flited pression and increased risk of DVT. Some stockings can be slight protomal the review as 0.4.200 mm Hg at the ankle. It was 10-200 revisits around the knee. Compression stockings ahould be flited pression stocking as house the flite include in the reliais includes in the review were below-knee compression stockings can be slightht/htkert than normal leg covering and can be potentia	Superficial vein thrombosis	13 per 1000					
Post-flight values eadem a score orderm a score order a			(2 10 10)	(0.10101.13)	, ,		
Oschräging in values groups was on control groups groups was on average (0, maximum edema. 6 to 9. 4.7 lower (9% Cl -4.9 to -4.5). See comment See comment Vulmonary embolus See comment See comment Not estimable 2821 (9 studies) See comment 0 participants developed pulmonary embolus in these studies. Vulmonary embolus See comment See comment Not estimable 2821 (9 studies) See comment 0 participants diel in these studies. Verse effects See comment See comment Not estimable 182 See comment 10 participants diel in these studies. Adverse effects See comment See comment Not estimable 182 See comment 10 participants diel in these studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the social of side effects in 4 studies. 1 1 All the stockings in the 9 triak inclued in this review were below-knee compression stockings. In four triaks the compression stockings should be fitted proving and the relative effect of the intervention groups and the relative effect of sine of the stocking vase serve obesly, limited mobility due to bone or of the studies, 148 the availability and coat of stock reaction and increase disk of DVT. Some stockings can be sightly thicker than normal lag covering and can be potentially reactor stock reaction and increase disk of DVT.	Oedema						
rom 0, no oedema, to control groups was on from average averag		ranged across	the intervention		(6 studies)	Low ⁴	
0, maximum 6 to 9. 4.7 lower (95% CI -4.9 to -4.5). 95% CI -4.9 to -4.5). Pulmonary embolus See comment See comment See comment See comment See comment Vertice (9 studies) studies, 5 Death See comment See comment Not estimable 2821 See comment 0 participants died in these studies. Adverse effects See comment See comment Not estimable 1182 See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI). CI: CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings and the share. Compression stockings can be slightly thicker than normal leg covering and can be potentially restriction and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restriction and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restriction to trave to ensure a good, comfortable fitting. Stockings ware put on 2 to 3 hours before the flight in most of the tristas. The availability and cost of stoc	from 0, no oedema, to						
(95% CI -4.9 to -4.5). Pulmonary embolus See comment See comment See comment See comment Pulmonary embolus in these studies. Peath See comment See comment Not estimable 2821 See comment 0 participants died in these studies. Adverse effects See comment See comment Not estimable 2821 See comment 0 participants died in these studies. Adverse effects See comment See comment Not estimable 1182 See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI). CI: CI: Confidence interval; RR: Risk ratio GRADE: GRADE: Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings and be slightly thicker than normal leg covering and can be potentially restricts tockings around the house prior to travel to ensure a good, comforable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc stricts around the house prior to travel to ensure a good, comforable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability restricts the studies, Aritiopants steler than 90 cm and heavier than 90 (kg. The incidence inte	10, maximum oedema.						
Pulmonary embolus See comment Not estimable 2821 See comment 0 participants developed pulmonary embolus in these studies. Peath See comment See comment Not estimable 2821 See comment 0 participants died in these studies. Adverse effects See comment See comment Not estimable 1182 See comment To the tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the intervention group and the relative effect of the intervention (and its 95% COI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings around the knee. Compression and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrict tockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the rule. The availability and cost of sto to that around the see with previous episodes of DVT. coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla aricopants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively.							
(9 studies) pulmonary embolus in these studies. Death See comment Not estimable 2821 (9 studies) See comment 0 participants died in these studies. Adverse effects See comment Not estimable 1182 (4 studies) See comment to the totarability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. Sumed risk in the intervention group and the relative effect of the intervention (and its 95% confidence interval) is based on the sasumed risk in the intervention group and the relative effect of the intervention (and its 95% COI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings are used as too tipid around the knee. Compression stockings can be slightly thicker than normal leg covering and can be potentially restrictin tookings around the house prior to travel to ensure a good, comfortable fitting. Stockings were up to a 10 a hours before the flight in most of the trials. The availability and cost of stoc structure in the sit factor) was 243%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase. Stockings were put on 210 hours before the flight risk participants was 1.45% and the articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td></td> <td></td>			· · · · · · · · · · · · · · · · · · ·				
(9 studies) studies. See comment See comment Not estimable 2821 See comment 0 participants died in these studies. Adverse effects See comment Not estimable 1182 See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the intervention group and the relative effect of the intervention (and its 95% CO). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trais included in this review were below-knee compression stockings. In four trials the compression stockings around the knee. Compression stockings around the knee. Compression stockings around the knee. Compression stockings are be slightly thicker than normal leg covering and can be potentially restrictive tockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the fight in most of the trais. The availability and cost of stoc trave trais recruited high risk participants defined as those with previous episodes of DVT, coagualation disorders, severe obesity, limited mobility due to bone or joint problems, neopla articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	Pulmonary embolus	See comment	See comment	Not estimable		See commen	
Adverse effects See comment See comment Not estimable 1182 See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the same of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings should be fitted privation and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive tockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc 'Two trials recruited high risk participants defined as those with previous episodes of DVT. coaguatation disorders, severe obesity, limited mobility due to bone or joint problems, neopla ariccear visit or, in one of the studies, participants tailer than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the iarticipants (with at least one risk factor) was 2.43%. We have rounded these of 10 0 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.					(9 studies)		
Adverse effects See comment See comment Not estimable 1182 (4 studies) See comment The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies. The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the issumed risk in the intervention group and the relative effect of the intervention (and its 95% C1). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20-30 mm Hg at the ankle. It was 10-20 different sizes. 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings should be fitted price size or is to topid around the knee. Compression and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive tookings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc "Two trials recruited high risk participants defined as those with previous episodes of DVT. coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	Death	See comment	See comment	Not estimable	2821	See commen	
(4 studies) (5 studies) (4 studies) (4 studies) (4 studies) (5 studie					(9 studies)		studies.
(* studies) very good with no complaints of side effects in 4 studies. ⁶ The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). C1: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20-30 mm Hg at the ankle. It was 10-20 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression stockings should be fitted pn he skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings were put on 2 to 3 hours before the flight in most of the trials. The availability moticated of stockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc: Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla articipants (with at least one risk factor) was 2.43%. We have rounded these off to 1 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	Adverse effects	See comment	See comment	Not estimable	1182	See commen	
The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four frials the compression stockings is how a 20-30 mm Hg at the ankle. It was 10-20 in different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted proteokings around the house prior to travel to ensure a good, confortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stock Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neoplas articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.					(4 studies)		
ssumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20:30 mm Hg at the ankle. It was 10:20 different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted pro te skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive cokings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stock Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neoplas aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the in articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.							
ssumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20:30 mm Hg at the ankle. It was 10-20 in different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted pro the skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive cockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stock Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neoplas aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the in articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.							
ssumed risk in the intervention group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20:30 mm Hg at the ankle. It was 10:20 different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted pro te skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive cokings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stock Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neoplas aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the in articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.							
CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations) 1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20-30 mm Hg at the ankle. It was 10-20 different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted pn e skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive tookings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the traits. The availability and cost of stoc Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla aricose veins or, in one of the studies, participants tailer than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the i articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.							dence interval) is based on the
1 All the stockings in the 9 trials included in this review were below-knee compression stockings. In four trials the compression strength was 20-30 mm Hg at the ankie. It was 10-20 different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted pr e skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive tookings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla articopants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.		• •					as evelopetions)
n different sizes. If a stocking is too tight around the knee it can prevent essential venous return causing the blood to pool around the knee. Compression stockings should be fitted p he skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restricts tockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopi aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	CI: Contidence interv	ai; RR: Risk	ratió GRADE:	GRADE Workin	ng Group grade	s of evidence (s	ee explanations)
he skin on a long flight and potentially cause ulceration and increased risk of DVT. Some stockings can be slightly thicker than normal leg covering and can be potentially restrictive tockings around the house prior to travel to ensure a good, comfortable fitting. Stockings were put on 2 to 3 hours before the flight in most of the trials. The availability and cost of stoc Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla aricose veries or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.							
Two trials recruited high risk participants defined as those with previous episodes of DVT, coagulation disorders, severe obesity, limited mobility due to bone or joint problems, neopla aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	the skin on a long fligh	nt and potential	ly cause ulceration	and increased	risk of DVT. S	ome stockings	can be slightly thicker than non
aricose veins or, in one of the studies, participants taller than 190 cm and heavier than 90 kg. The incidence for 7 trials that excluded high risk participants was 1.45% and the i articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	-	-	-				
articipants (with at least one risk factor) was 2.43%. We have rounded these off to 10 and 30 per 1,000 respectively. The confidence interval crosses no difference and does not rule out a small increase.	varicose veins or, in o	one of the studi	es, participants ta	iller than 190 cm	and heavier t	han 90 kg. The	incidence for 7 trials that excl
	participants (with at lea	ast one risk fact	or) was 2.43%. W	e have rounded t	hese off to 10	and 30 per 1,00	0 respectively.
The measurement of oedema was not validated or blinded to the intervention. All of these studies were conducted by the same investigators.	³ The confidence inter	val crosses no	difference and doe	s not rule out a s	mall increase.		
	⁴ The measurement of	foedema was n	ot validated or blin	ded to the interv	ention. All of th	ese studies wer	re conducted by the same invest

⁵ If there are very few or no events and the number of participants is large, judgement about the quality of evidence (particularly judgements about precision) may be based on the absolute effect. Here the quality rating may be considered "high" if the outcome was appropriately assessed and the event, in fact, did not occur in 2821 studied participants.

⁶ None of the other trials reported adverse effects, apart from 4 cases of superficial vein thrombosis in varicose veins in the knee region that were compressed by the upper edge of the stocking in one trial

Figure 1 Snapshot of a Summary of Findings (SoF) table.

quality of two bodies of evidence is similar (for example, randomized trials and observational studies), SoF tables may include summaries of both. It is also possible that review authors found no published evidence regarding one or more critical or important outcomes.

Baseline risk

An important issue for decision-making is the determination of a baseline risk for a particular patientimportant outcome. GRADE recognizes that the patients in randomized trials may be unrepresentative of the general population (for example, they may have been selected for being at high risk, thereby reducing sample size requirements) and that this baseline risk varies for prognostic subgroups. Therefore, calculating absolute measures of effect size directly from the data from randomized trials may be misleading. Instead, baseline or control group risk should be drawn from well-designed observational studies if available [12].

If high quality observational studies are not available, GRADE suggests using the median risk (rather than the weighted average, which is influenced by outliers) among the control groups in the included studies. If there is important variation on control group risk, GRADEPro software (computer program developed by Jan Brozek, Andy Oxman and Holger Schunemann) (provides the opportunity for authors to present a range of risks upon which the calculation of absolute effect size measures is then based. To date, GRADE has shied away from also seeking to quantify the uncertainty surrounding the estimates of baseline risk [12]. This has been a pragmatic decision to avoid additional complexity, which may make the systematic review process unmanageable.

Effect size presentation

Based on studies of consumer numeracy, effect size presentation as natural frequencies, that is, as event per 100 patients, for example, is preferred over presentation of relative risks [13]. Recent data (from ongoing research), however, suggest percentages may do as well and sometimes better. User testing of evidence profiles of guideline panelists randomized to four different presentation features has further documented the value of presenting absolute risk differences [14]. Whether or not to include them was an issue of intense debate at the GRADE working group meeting, held in conjunction with the Cochrane Colloquium in Sao Paolo (2007). Absolute measures of effect should be presented in conjunction with confidence intervals reflecting the underlying precision and indicate the length of follow-up to which estimates refer.

Whereas relative and absolute effect sizes used to report the results of dichotomous measures are very familiar to clinical audiences, summary measures for continuous outcomes present particular challenges to interpretation [15]. The most common approach divides the difference in means in each study by its standard deviation and presents pooled results in standard deviation units (standardized mean difference). Its drawbacks include the vulnerability to heterogeneity and difficulties in interpretation.

One approach advocated in the interest of improved interpretability is the reporting in minimal important difference (MID) units, when the MID is known. Another related approach is to use the MID as the threshold value for converting a continuous outcome into a binary outcome and then presenting relative and absolute effect sizes [15].

Uptake of SoF tables

Since 2008, the uptake of SoF tables in Cochrane Reviews has increased steadily. In Issue 1, 2009 (quarterly issue) of *The Cochrane Library*, 3 reviews included a SoF

table, and this number had increased to 94 reviews in the Issue 1 to 3, 2012 (monthly issues). In March 2012, a total of 502 Cochrane Reviews included one or more SoF tables. The quality of this set of SoF tables is currently being evaluated by the ARMG. As of September 2013, almost one thousand reviews include a SoF table.

According to the Methodological Standards for the conduct of new Cochrane Intervention Reviews, including a SoF table is highly desirable and assessing the quality of the body of evidence is mandatory for new Cochrane Intervention Reviews.

Added value of SoF tables

The added value of SoF tables was first evaluated in 2005, in an unpublished pilot study headed by Gunn Vist in collaboration with Andy Oxman, Paul Glasziou, Julian Higgins and Holger Schünemann. Twenty authors from 17 Cochrane Review Groups (CRGs) were asked to construct a SoF table for their new or updated review. The authors spent on average an additional 4 hours (range 2 to 40 hours) on their review in order to do this. In general, the authors reported that the layout of the SoF Table was clear, and that presenting the review results in a SoF table was found to be helpful. Of the 17 CRGs, 11 concluded that the accessibility of the review was increased, 5 CRGs concluded that the quality of the review was improved and 1 CRG rephrased the conclusions. Most CRGs experienced software difficulties.

The added value of SoF tables was also tested in users of Cochrane Reviews. Two small randomised trials found that including a SoF table in a systematic review improved the user understanding and rapid retrieval of key information [5]. However, the uptake of SoF by review authors has not been optimal. There may be several reasons for this. The standard table does not provide review authors with enough flexibility to accommodate for different kinds of reviews. Some people also perceive the tables to be compact and full of data making them too complex for the users (see Figure 1).

During development, user testing of these tables had revealed one of the main challenges as a "tension between achieving precision and simplicity" [5], where precision refers to comprehensiveness. Comprehensiveness, however, to an untrained eye, can quickly become visual clutter that camouflages the main messages.

The SoF development team addressed this tension by using a layered approach, allowing some parts of the table to emerge as more important to the eye than other parts, through typographical and color differentiation. However, this typographical layered approach was largely not implemented due to the difficulty of technical implementation in website and PDF formats, compromising the balance of precision and simplicity. The full extent, however, to which SoF tables aid, or change, decision making has not yet been formally investigated.

Further and future developments

Currently, the ARMG and GRADE Working Group are working on further development of the SoF tables in two research projects. One research project, funded by Cochrane Methods Innovation Fund, evaluates the degree of acceptable flexibility beyond standard presentation of SoF tables. This evaluation includes investigating which alternative columns are acceptable to decision makers and should be included as alternatives in SoF tables, for example, the addition of risk differences and number needed to treat instead of the currently used columns of assumed and corresponding risk. This evaluation will also include development of descriptions for outcomes that could not be pooled, which columns can be collapsed and which comparisons should be described in the primary SoF tables. The second aim of the project is to provide guidance on the standardization of comments and footnotes for SoF tables, with a focus on the explanations for downgrading and upgrading the quality of a body of evidence. The third aim is to develop guidance on what information to include in SoF tables in diagnostic test accuracy reviews. The results of this work, expected at the end of 2013, will be integrated in updated training material to provide optimal guidance to reviewer authors and users of reviews.

The DECIDE project, initiated and developed by the GRADE working group, which runs from 2011 to 2015 (www.decide-collaboration.eu), attempts to take advantage of technological advances to improve the SoF table. As a result, the interactive SoF table (iSoF) uses electronic presentation of information to reconcile precision and simplicity through a layered approach to information presentation. The top layer presents basic information, while the deeper layers allow access to more details on demand. In addition, the user has control over how many and which outcomes the table displays and in which format (words, numbers, graphics) (see Figure 2).

The iSoF also has a column to express results in a narrative format in addition to statistical formats, or in lieu of these when statistical data are not available. The multiple representation possibilities make the table more flexible for presenting data from different kinds of reviews.

Additional advantages of the iSoF include an interactive presentation and explanation of confidence intervals and other statistical terms, and a responsive format for printing and for displaying on different sizes and types of electronic devices.

Future plans include the translation of the iSoF into different languages. The iSoF will be incorporated in GRADEpro and possibly other interfaces (for example, Cochrane Reviews, guideline products, electronic medical records). The different versions would present the same core information in potentially variable formats.

Plain language summary


The plain language summary (PLS, formerly called 'synopsis') aims to summarize the results of a review in such a way that consumers of health care without a medical background can readily understand them. The current format of the PLS was informed by a qualitative study among consumers [6]. PLS has two parts: a title and a body of test. In an effort to better disseminate Cochrane evidence synthesis among consumers, efforts are underway to include a PLS in PubMed Health, a freely accessible service by the US National Library of Medicine. Ongoing improvement efforts are being directed towards assuring consistency between the review and the PLS, implementing short yet concise titles and reconsidering the current word count limit of 400 words, while maintaining understandability.

Example of a plain language summary [16]: compression stockings for preventing deep vein thrombosis (DVT) in airline passengers.

In the last few years, there has been increasing interest in whether compression stockings (sometimes called 'flight socks') reduce the risk of DVT (blood clots in the legs) and other circulatory problems in airline passengers. The stockings are worn throughout the flight and are similar to those known to be effective in patients lying in bed after an operation. By applying a gentle pressure, to the ankle in particular, compression stockings help blood to flow. Pressure combined with leg movement helps blood in superficial veins to move to the deep veins and back to the heart. The blood is then less likely to clot in the deep veins, which could be fatal if the clot moves to the lungs.

Wearing compression stockings resulted in a very large reduction in symptomless DVT among airline passengers who were allocated to wear compression stockings compared to those allocated not to wear such stockings. People who wore stockings also had much less discomfort and swelling in their legs (edema) than those who did not wear them.

These conclusions were based on nine trials, which studied over 2,800 people, about half of whom were randomly assigned to wearing stockings for a flight lasting at least seven hours while the other half did not. None of the passengers developed a DVT with symptoms (slowly developing leg pain, swelling and increased temperature) and no serious events (a blood clot in their lungs (pulmonary embolus) or dying) were reported. Passengers were carefully assessed after the flight to detect any problems with the circulation of blood in their legs, even if they had not noticed any problems themselves. There was a big difference in symptomless DVT



between the two groups, equivalent to a reduction in the risk from a few 10s per thousand passengers to 2 or 3 per thousand. Not all the trials reported on possible problems with wearing stockings but in those that did, the researchers said that the stockings were well tolerated, without any problems.

In connection with the SoF tables, research has been conducted on how to communicate the results of systematic reviews to consumers and how these are perceived and understood [6,7,17]. This work is currently feeding into the Plain Language Expectations for Authors of Cochrane Summaries (PLEACS) project. The PLEACS group has developed a set of minimum criteria for the content of PLS (www.consumers.cochrane.org/PLEACS). The purpose is to ensure that authors convey the key question and findings of the review in a succinct and clear manner to consumers. The group is also working on improving the narrative reporting of results by testing the inclusion of headings and numbers.

Current efforts include the development of a standardized language to describe statistical results based on effect size and quality of supporting evidence [6]. This standardized language could be used in PLS and also in abstracts of Cochrane Reviews. The iSoF project is prototyping the use of PLS standardized sentences in their own column in the table, providing the reader with a narrative explanation of the gist of the results, next to the numbers. The Collaboration is currently exploring how standardized language could contribute to ensuring the quality of translation of PLS and abstracts.

Future direction of PLS and SoF tables

A major future direction for the presentation formats of PLS and SoF tables is making both of them usable by both audiences and cross-linking them for those who are interested in both. One could conceptualize PLS and SoF tables, in particular, as the basic building blocks for dissemination to end-users. Producing high quality PLS and SoF tables and making them compatible and linked would make it easy to produce dissemination products targeting different audiences (for example, providers, health policy makers [17], the press, guideline developers).

Furthermore, to avoid the risk of a one-size-fits-all approach to all recommendations, issues of who to apply results to and attempting to divide them into different risk groups (low, medium, high) deserves more work in the future.

Training, support and tools

Among the core functions of the ARMG are training, providing specialist advice and contributing to software development. Following the first GRADE Working Group articles published in 2003 and 2004, the *British Medical Journal* published a series of papers on the GRADE approach in 2004, authored by the GRADE Working Group. Subsequently, in 2011, publication of a series of 20 papers in the Journal of Clinical Epidemiology started. The first series provides the basics of the GRADE approach, while the second series offers detailed guidance on applying GRADE and constructing SoF tables. Among the (local) training activities are the GRADE/SoF workshops run by the Dutch and German Cochrane centers and McMaster University, and pre-conference and conference workshops at Cochrane Colloquia and the meetings of the Guidelines International Network. Examples of online training initiatives are the McMaster GRADE Online Learning Modules (cebgrade.mcmaster.ca), YouTube videos and the slidecast presentations of Cochrane Training. In February 2013, the ARMG launched a question and answer webinar series. To increase the capacity of training and support, the ARMG is currently creating a network of members who can be consulted for advice and support on making SoF tables and GRADE profiles. Most of the support is currently provided by members of the ARMG at McMaster University who have already helped many authors of Cochrane Reviews. The new version of GRADEpro, which will include training exercises and links to training material, will be part of the Guideline Development Tool (www. guidelinedevelopment.org), a comprehensive new tool for developing evidence-based guidance. An update of the currently available two chapters of the ARMG in the Cochrane Handbook for Systematic Reviews on Interventions is expected in 2013 [3,18].

Current debates and challenges

Current issues of debate and controversy include optimal presentation formats of SoF tables, the training and perceived additional effort involved in using GRADE, and the extent to which authors of Cochrane Reviews should provide explicit guidance to target audiences of patients, clinicians and policy-makers. The first of these should be settled by ongoing empirical investigation and the interactive SoF table. The other two issues may be more challenging to solve. Criticisms of GRADE include its complexity, the time involved in its application, and the extent to which its application yields ratings of low confidence in effect estimates. GRADE proponents argue that the complexity is not in GRADE but in the issues that GRADE has brought to light (for example, complex judgments related to precision, directness and consistency, and thresholds for when to rate down confidence regarding these components and for risk of bias). If one is going to address, rather than ignore, these issues, GRADE provides a structure that simplifies, rather than increasing the complexity. GRADE proponents also argue that the time required is in preparing summaries that allow one to address the issues of evidence evaluation, rather than in the evaluation itself. GRADE may indeed lower the workload by providing a structure to what has often been an unstructured and, therefore, more disorganized and laborious effort. With respect to the issue of the likelihood that application of GRADE will result in conclusions of low confidence in effect estimates, paucity of high quality evidence is not the fault of GRADE or the SoF table.

More importantly, GRADE and ARMG are attentive and respectful to these concerns. Where this attentiveness plays out vividly at the moment is in the cautious approach to dealing with uncertainty related to baseline risk or diagnostic test accuracy studies. Greater attention to this up to now relatively neglected area will increase complexity, may increase time required, and will increase the likelihood of ratings of low confidence in effect estimates. GRADE is currently working on advancing our conceptual understanding of these issues and providing a way to advance their consideration while minimizing associated burdens on systematic review authors and guideline developers.

The Cochrane Collaboration is explicit that systematic review authors should not make recommendations. At the same time, audiences seek guidance on how results should be applied, and Cochrane provides the opportunity for authors to reflect on the implications of their review for clinical practice and public policy. These competing considerations create tension. A potential solution in the clinical, and perhaps the health policy area, is for authors to highlight particular constellations of values and preferences and their implications, given the results, for particular courses of action.

Abbreviations

ARMG: Applicability and Recommendation Methods Group; CRGs: Cochrane Review Groups; DVT: Deep vein thrombosis; EP: Evidence profiles; GRADE: Grading of recommendations assessment, development and evaluation; iSof: Interactive summary of findings table; MID: Minimal important difference; MIF: Methods innovation fund; PLEACS: Plain Language Expectations for Authors of Cochrane Summaries; PLS: Plain language summary; SoF: Summary of Findings.

Competing interests

All authors are members of the ARMG and GRADE Working Group. GG and HS are co-convenors of the ARMG and co-chairs of the GRADE Working Group.

Authors' contributions

ML, EA and HS developed the outline of the manuscript. All authors contributed to the writing of the manuscript and critically reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We greatly acknowledge Nancy Santesso, Sarah Rosenbaum, Gabriel Rada, Claire Glenton and Andy Oxman for their contribution to the paper.

Author details

¹The Dutch Cochrane Centre, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ²Department of Internal Medicine, American University of Beirut, Riad El Solh St, Beirut, Lebanon. ³Department of Urology and Prostate Disease Center, University of Florida, College of Medicine, Gainesville, FL, USA. ⁴Malcom Randall Veterans Administration Medical Center, Gainesville, FL, USA. ⁵Centre for Research in Evidence-Based Practice, Faculty of Health Sciences, Bond University, Gold Coast, QLD, Australia. ⁶Departments of Clinical Epidemiology and Biostatistics and Medicine, McMaster University Health Sciences Centre, Hamilton, ON, Canada. Received: 9 May 2013 Accepted: 12 September 2013 Published: 23 September 2013

References

- Glasziou PP, Irwig LM: An evidence based approach to individualising treatment. BMJ 1995, 311:1356–1359.
- O'Connell D, Glasziou P, Hill S: How to Use the Evidence: Assessment and Application of Scientific Evidence. Handbook series on Preparing Clinical Practice Guides. NHMRC: Canberra, ACT, Australia; 2000.
- Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH: Chapter 12: Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Edited by Higgins JPT, Green S. The Cochrane Collaboration; 2011. Available from http://www.cochrane-handbook.org.
- Rosenbaum SE, Glenton C, Oxman AD: Summary-of-findings tables in Cochrane reviews improved understanding and rapid retrieval of key information. J Clin Epidemiol 2010, 63:620–626.
- Rosenbaum SE, Glenton C, Nylund HK, Oxman AD: User testing and stakeholder feedback contributed to the development of understandable and useful summary of findings tables for Cochrane Reviews. J Clin Epidemiol 2010, 63:607–619.
- Glenton C, Santesso N, Rosenbaum S, Nilsen ES, Rader T, Ciapponi A, Dilkes H: Presenting the results of Cochrane Systematic Reviews to a consumer audience: a qualitative study. *Med Decis Making* 2010, 30:566–577.
- Santesso N, Glenton C, Rader T, Strømme-Nilsen E, Moja L, Pardo JP, Ciapponi A, Schünemann H: A New Format for Plain Language Summaries: Does It Improve Understanding, and is It Useful and Preferable? A Randomized Trial. 17th edition. Singapore: Cochrane Colloquium; 2009.
- Akl EA, Schünemann HJ: Routine heparin for patients with cancer? One answer, more questions. N Engl J Med 2012, 366:661–662.
- Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ: GRADE guidelines: 1 introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011, 64:383–394.
- Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group: Grading quality of evidence and strength of recommendations. *BMJ* 2004, 328:1490.
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ: What is "quality of evidence" and why is it important to clinicians? *BMJ* 2008, 336:995–998.
- Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schünemann HJ: GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013, 66:158–172.
- 13. Gigerenzer G, Edwards A: Simple tools for understanding risks: from innumeracy to insight. *BMJ* 2003, **327**:741–744.
- Vandvik PO, Santesso N, Akl EA, You J, Mulla S, Spencer FA, Johnston BC, Brozek J, Kreis J, Brandt L, Zhou Q, Schünemann HJ, Guyatt G: Formatting modifications in GRADE evidence profiles improved guideline panelists comprehension and accessibility to information: a randomized trial. J Clin Epidemiol 2012, 65:748–755.
- Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R, Schünemann HJ: GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes. J Clin Epidemiol 2013, 66:173–183.
- Clarke M, Hopewell S, Jusczczak E, Eisinga A, Kjeldstrom M: Compression stockings for preventing deep vein thrombosis in airline passengers. *Cochrane Database Syst Rev* 2006, 19, CD004002.
- Rosenbaum SE, Glenton C, Wiysonge CS, Abalos E, Mignini L, Young T, Althabe F, Ciapponi A, Marti SG, Meng Q, Wang J, la Hoz Bradford AM, Kiwanuka SN, Rutebemberwa E, Pariyo GW, Flottorp S, Oxman AD: Evidence

summaries tailored to health policy-makers in low- and middle-income countries. Bull World Health Organ 2011, 89:54–61.

 Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH, on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group: Chapter 11: Presenting results and 'summary of findings' tables. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Edited by Higgins JPT, Green S. The Cochrane Collaboration; 2011. Available from http://www. cochrane-handbook.org.

doi:10.1186/2046-4053-2-81

Cite this article as: Langendam *et al.*: Assessing and presenting summaries of evidence in Cochrane Reviews. *Systematic Reviews* 2013 2:81.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit